Diego Martin Cecchini

Dr. Diego Martin Cecchini

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2007 in AIDS
Verified
Journal Article
Closed access
Diego Martin CecchiniDiego Martin Cecchini
Diego Martin Cecchini
JAJuan Ambrosioni
Juan Ambrosioni
CBClarisa Brezzo
Clarisa Brezzo
MCMarcelo Corti
Marcelo Corti
ARAna Rybko
Ana Rybko
MAMarta Ambroggi
Marta Ambroggi
The objective of this study was to identify prognostic factors of death in patients with tuberculous meningitis (TM) and show the impact of infection by multidrug-resistant strains on the outcome of this disease. We retrospectively analysed clinical charts of HIV-infected patients with culture-confirmed TM attending our institution during 1996–2004. The following variables were associated with death during hospitalization: neurological signs at admission, a CD4 T-cell count less than 50 cells/μl and infection by multidrug-resistant strains.

12 August 2005 in AIDS
Verified
Journal Article
Closed access
Diego Martin CecchiniDiego Martin Cecchini
Diego Martin Cecchini
JAJuan C Ambrosioni
Juan C Ambrosioni
GAGomez Abel
Gomez Abel
BFBiscione Fernando
Biscione Fernando
OTOrduna Tomás
Orduna Tomás
BJBenetucci Jorge
Benetucci Jorge

1 July 2005 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
FBFernando Biscione
Fernando Biscione
Diego Martin CecchiniDiego Martin Cecchini
Diego Martin Cecchini
JAJuan Ambrosioni
Juan Ambrosioni
MBMario Bianchi
Mario Bianchi
MCMarcelo Corti
Marcelo Corti
JBJorge Benetucci
Jorge Benetucci

28 August 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
MFMaria Ines Figueroa
Maria Ines Figueroa
Carlos BritesCarlos Brites
Carlos Brites
Diego Martin CecchiniDiego Martin Cecchini
Diego Martin Cecchini
ARAline Ramalho
Aline Ramalho
JFJose Luis Francos
Jose Luis Francos
DADamián Aguila
Damián Aguila
Background: Dolutegravir (DTG)/lamivudine dual therapy (DT) has demonstrated noninferiority to triple therapy (TT) in the GEMINI trials. Although the population with ≤200 CD4 cells/mm3 had a lower response rate, this was unrelated to virological failure. This trial evaluated the antiviral activity of dolutegravir/lamivudine among antiretroviral therapy (ART)-naive patients with human immunodeficiency virus (HIV) with a CD4 count ≤200 cells/mm3. Methods: DOLCE is a randomized, hypothesis-based, open-label, multicenter study l, assessing the antiviral efficacy of DTG/3TC at week 48 in treatment-naive people with HIV (PWH) with CD4 counts ≤200 cells/mm3. Participants were randomly assigned in a 2:1 ratio to receive DTG/3TC as a single tablet regimen or DTG plus Tenofovir disoproxil fumarate (TDF)/XTC: Emtricitabine or lamivudine (FTC or 3TC). The primary endpoint was the proportion of participants with pVL <50 copies/mL at week 48 (Food and Drug Administration snapshot analysis intent-to-treat exposed population). This report presents results at week 48. Results: Baseline characteristics were similar in both arms. In the DT arm, median CD4 cell count was 109 cells/mm (interquartile range [IQR]: 49–177) and median pVL was 180,000 copies/mL (IQR: 53 309–468 691); 45.4% had CD4 100 000 copies/mL. CDC (Centers for Disease Control and Prevention) stage C: 31.4%. At week 48, virological suppression (pVL <50 copies/mL) was achieved 82.2% in the DT (125/152), and the CD4 count increased by +200 cells/mm3. Per-protocol analysis showed a response rate of 91.9%. Severe adverse events (n = 17) were reported in 15 of 152 participants (11.1%). Conclusions: Dolutegravir/3TC demonstrated high efficacy in a population with low CD4 counts and high viral load. This study adds information regarding the efficacy and safety of DTG/3TC, regardless of baseline CD4 counts and viral load. Clinical Trials Registration: NCT04880395.

14 June 2017 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
Diego Martin CecchiniDiego Martin Cecchini
Diego Martin Cecchini
MMMarina G. Martinez
Marina G. Martinez
LMLaura M. Morganti
Laura M. Morganti
CRClaudia G. Rodriguez
Claudia G. Rodriguez
We conducted a retrospective study in a general hospital in Buenos Aires, Argentina (2009-2015) aimed at evaluating outcomes in HIV-infected pregnant women (HIPW), who were prescribed raltegravir (RAL)- containing antiretroviral therapy (ART). A total of 239 HIPW were enrolled in our study; among them 31 received RAL (12.9%) at different clinical stages: i) intensification (INS): addition of RAL to current ART because of detectable antepartum viral load, 13 (41.9%); ii) late presenter (LP): standard ART + RAL as fourth drug, 15 (48.4%); iii) treatment of resistant-HIV: 3 (9.7%). Median gestational age at RAL initiation was 34 weeks and median exposure was 30 days. In INS-group, median viral load (VL) decrease was 1.48 log10. In LPgroup, median VL decline was 2.15 log10. No clinical adverse events or maternal intolerance attributable to RAL were observed. Elective cesarean section was done in 51.7%; mild elevation of transaminases was observed in 35% of neonates. No vertical transmission was documented.

9 May 2023 in Viruses
Verified
Journal Article
Open access
PDF file
MRMaría F. Rombini
María F. Rombini
Diego Martin CecchiniDiego Martin Cecchini
Diego Martin Cecchini
SMSofía Diana Menendez
Sofía Diana Menendez
LCLiliana Calanni
Liliana Calanni
RCRosana Cuini
Rosana Cuini
OTon behalf of the COVIDARE Study Team
on behalf of the COVIDARE Study Team
Tenofovir has been hypothesized to be effective against COVID-19 and is available as two prodrugs, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), both part of antiretroviral therapy (ART) regimens. People living with human immunodeficiency virus (PLWH) might be at higher risk for COVID-19 progression; however, information about the impact of tenofovir on COVID-19 clinical outcomes remains controversial. The COVIDARE is a prospective observational multicentric study in Argentina. PLWH with COVID-19 were enrolled from September 2020 to mid-June 2022. Patients were stratified according to baseline ART into those with tenofovir (TDF or TAF) and those without. Univariate and multivariate analyses were performed to evaluate the impact of tenofovir vs. non-tenofovir-containing regimens on major clinical outcomes. Of the 1155 subjects evaluated, 927 (80%) received tenofovir-based ART (79% TDF, 21% TAF) whilst the remaining population was under non-tenofovir regimens. The non-tenofovir group had older age and a higher prevalence of heart and kidney disease. Regarding the prevalence of symptomatic COVID-19, tomographic findings, hospitalization, and mortality, no differences were observed. The oxygen therapy requirement was higher in the non-tenofovir group. In the multivariate analyses, a first model with adjustment for viral load, CD4 T-cell count, and overall comorbidities showed that oxygen requirement was associated with non-tenofovir ART. In a second model with adjustment by chronic kidney disease, tenofovir exposure was not statistically significant.